Home
About
Overview
Sharing Data
ORCID
Help
History (92)
Endovascular Therapy for Patients With Low NIHSS Scores and Large Vessel Occlusion in the 6- to 24-Hour Window: Analysis of the CLEAR Study.
Skeletal myotubes expressing ALS mutant SOD1 induce pathogenic changes, impair mitochondrial axonal transport, and trigger motoneuron death.
Conservative treatment of uveal melanoma: probability of eye retention after proton treatment.
Allotransplantation for patients age =40 years with non-Hodgkin lymphoma: encouraging progression-free survival.
ESGCT 2022: The New Normal for the Gene Therapy Community.
See All 92 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
ESGCT 2022: The New Normal for the Gene Therapy Community.
Flotte TR. ESGCT 2022: The New Normal for the Gene Therapy Community. Hum Gene Ther. 2022 09; 33(17-18):841.
View in:
PubMed
subject areas
Community Health Services
Genetic Therapy
Humans
authors with profiles
Terence R Flotte MD